av Øivind Enger | mar 23, 2021 | News
The Norwegian Investment Company Saga Pure ASA has entered into an agreement to invest NOK 75 mill into Sarsia Seed portfolio company Heimdall Power AS to help accelerate the company’s growth strategy. The total transaction was 155mNOK involving existing...
av Øivind Enger | jan 19, 2021 | News
Sarsia Seed portfolio company Coegin Pharma AB was yesterday listed on Nordic SME stock exchange. (Ticker: COEGIN) Read...
av Øivind Enger | okt 7, 2020 | News
Sarsia Seed portfolio company Vaccibody AS – was today listed on Oslo Stock Exchange´s Merkur Markets list. ...
av Øivind Enger | okt 1, 2020 | News
It was announced today that Sarsia Seed portfolio company Vaccibody AS enters into $715m lisence and collaboration agreement with Genentech.Low double-digit tiered royalties on sales of commercialized products arising from the partnership are in addition. ...
av Øivind Enger | aug 17, 2020 | News
Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR) announce that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO,...
av Øivind Enger | mai 28, 2020 | News
Vaccibody announces First Patient Dosed in its VB C-02 trial; a multi-centre, open-label Phase II clinical trial testing a combination of Vaccibody’s VB10.16, a targeted DNA vaccine, and Roche’s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in...
